Disease · EFO_0008496

chronic hepatitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic hepatitis. Diseases, record EFO_0008496. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0008496

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic hepatitis; Open Targets
Open Targets ID: EFO_0008496; Open Targets
NCI Thesaurus: C82978; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 3 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RIBAVIRIN	CHEMBL1643	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
IODINE	CHEMBL1201225	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
DANOPREVIR	CHEMBL258734	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
INTERFERON ALFA-2A	CHEMBL2108508	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RITONAVIR	CHEMBL163	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IFNAR1	Interferon alpha/beta receptor	2	Interferon alpha/beta receptor agonist	Phase 3	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	2	Interferon alpha/beta receptor agonist	Phase 3	https://conductscience.org/library/genes/3455	Drugs and targets
CYP3A4	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Phase 2	https://conductscience.org/library/genes/1576	Drugs and targets
CYP3A43	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Phase 2	https://conductscience.org/library/genes/64816	Drugs and targets
CYP3A5	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Phase 2	https://conductscience.org/library/genes/1577	Drugs and targets
CYP3A7	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Phase 2	https://conductscience.org/library/genes/1551	Drugs and targets
IMPDH1	Inosine-5'-monophosphate dehydrogenase 1	1	Inosine-5'-monophosphate dehydrogenase 1 inhibitor	Phase 3	https://conductscience.org/library/genes/3614	Drugs and targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03020004	Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II	Phase 2	70	2018-02-07	Chronic Hepatitis C	DANOPREVIR, INTERFERON ALFA-2A, RIBAVIRIN, RITONAVIR	Its record names the disease	ClinicalTrials.gov
NCT01463592	To Study the Efficacy and Safety of Renessans in Chronic HCV Patients	Phase 3	90		Hepatitis C, Chronic	INTERFERON ALFA-2B, RIBAVIRIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0008496

GET https://conductscience.org/api/diseases/v1/EFO_0008496/drugs

API reference For AI assistants